Taking CRM to the Next Level: Web-assisted relationship- and community-building for the pharmaceutical industry | $3800
CRM is a business strategy by which a company seeks to maximize the value of its products by managing the customer relationship, with specific aims to boost customer retention and increase market share, while reducing the costs of sales, marketing and customer fulfillment. CRM is made necessary because of advances in Web-enabled technologies, which have changed the dynamics of sales and marketing.

Mid Pharma Sector: In-licensing and other externalization strategies | $7600
Mid Pharma companies are EU/US based pharmaceutical companies with 2005 annual revenues of < $10bn. An integral component of the Mid Pharma business model is securing access to promising new drugs through in-licensing and acquisition.

Pharmaceutical Outsourcing Part 1: Contract Manufacturing Strategies - Offshoring is not the only option to drive productivity and efficiencies | $7600
The dynamics of the contract manufacturing landscape in the pharmaceutical industry are changing. With the increasing globalization of the contract manufacturing market, particularly regarding on-patent biologics and APIs, companies need to position themselves to be able capture the cost savings Asian countries have to offer.

Global Generics Guide: Part 2 - Benchmarking country markets and strategic issues | $15,200
The generics market is undergoing significant change, with intense merger and acquisition activity, a raft of upcoming patent expiries and new legislation being enacted to promote generic prescription in the major markets. In addition, key issues, such as authorized generics, the first biosimilars approvals and increasing competition within the market are also affecting growth dynamics.

Pricing and Reimbursement in the US: Innovation and robust pharmacoeconomic analysis are key | $11,400
The US is the leading global drugs market in terms of sales and profit margin. However, drug companies are facing an unprecedented number of challenges in maintaining revenue growth: fewer drugs are being approved, a wide number of blockbusters are facing patent expiry, and payers are implementing stringent cost-containment policies in the face of sky-rocketing healthcare costs.

The Pharmaceutical Company Outlook to 2011: Financial and Strategic Analysis of the Sales Outlook for Big Pharma, Mid Pharma, Japan Pharma and Biotech | $7600
Based on an analysis of 46 companies and 1,000+ products, Datamonitor forecasts that pharmaceutical industry ethical sales will increase at a modest 4.9% CAGR 200511. However, behind this industry average figure there are strategic segments of the market that offer double-digit growth rates through barriers against generic competition and the opportunity for aggressive indication broadening.

Chinese Pharmaceutical Market Overview - Regulatory reform and the evolving healthcare market provide opportunities in china | $15200
The Chinese pharmaceutical market, although only positioned ninth globally, has experienced pronounced and rapid expansion in recent years, driven by the growth of both Chinese and Western manufacturers. Increasingly, there is a shift towards a research-based industry, focused on generating new, innovative therapies, supported by improving intellectual property regulations.

Targeting Profitable Consumer Trends In Brazil, Russia, India and China | $5695
Brazil, Russia, India and China (BRIC) markets have huge potential for the development of a stable consumer society that can be profitably targeted by consumer packaged goods players across the globe. Although the region requires further social cohesion and economic development to fully stabilize, players that act quickly and tailor their offering can reap significant rewards.

Reinvigorating On-Trade Sales 2007 | $5695
Reinvigorating On-Trade Sales 2007 shows how, despite some recent tough times in this part of the alcoholic drinks market, there are significant opportunities for those able to develop targeted new products and invest in relevant point-of-sale marketing campaigns. On-trade occasions can be developed that are more in keeping with today's growing demographic groups and mass market lifestyles.

Optimizing Sales Force Effectiveness - From quantity to quality | $7600
The environment in which pharmaceutical companies promote their products has become increasingly tough over recent years as a number of trends and factors drive changes. As the effects of shrinking pipelines and rising R&D costs impact companies, they are under increasing pressure to deliver greater productivity from their sales forces.

Emerging eHealth Technologies: Key trends impacting the physician-patient relationship | $3800
Internet-enabled information communication technologies, such as computers, mobile phones and PDAs have had a significant impact on the physician-patient relationship by allowing for the efficient and cost-effective management of large volumes of information, as well as by supporting communications between individuals that would otherwise be prohibited by time or geography.

Pricing and Reimbursement in Japan: Costly healthcare system inefficiencies increase the focus on healthcare cost containment | $3800
The government has relied on simple P&R tools to contain rising healthcare costs and provide a reasonable level of healthcare. However, factors such as a healthier elderly population are masking healthcare system inefficiencies, boosting healthcare costs and increasing the focus on cost containment. Although the rise in drug spending is slowing down, it remains a visible cost containment target.

Pricing & Reimbursement in Europe: Can the drive for cost effectiveness overcome cost containment? | $11,400
Combined drug sales in the five major European markets represent the second-biggest market globally after the US. Unlike the US, which is dominated by a wide range of private payers, governments are the major payers in Europe. The monopsonistic nature of these markets provides governments with significant leverage and they use extensive P&R controls to contain spiralling healthcare costs.

Reformulation Strategies - Comparisons of Past and Future Reformulation Strategies | $7600
Product lifecycle management (LCM) is an integral part of portfolio continuation and preservation. With R&D productivity stalling, and profit margins increasingly eroded by cost-containment initiatives, maximizing the return on investment (ROI) of in-line brands is a key objective for pharmaceutical companies.

Outlook for eDetailing: What does Next Generation eDetailing Look Like? | $3800
Brand teams can use eDetailing to expand physician coverage and improve the quality of the services provided to dedicated prescribers. However, despite early positive indications within the market, Datamonitor finds that many physicians have lost interest in receiving information through eDetailing channels.

Pharmaceutical Outsourcing Part 2: An Introduction to Drug Discovery Strategies - new opportunities lie in a fully integrated global outsourcing strategy | $3800
The pharma industry is facing a crisis over R&D productivity, as reflected by the low level of new drug approvals despite companies investing the highest ever amounts in R&D. As a result, companies are seeking novel ways to drive growth, with many opting to increase their reliance on third parties - through licensing, collaborative and outsourcing agreements - in an attempt to achieve this.

Patients as Consumers: Understanding the Increasing Consumer Level of Influence in Healthcare | $3800
According to Datamonitor's eHealth Consumer Insight Survey, consumers in the US, Western EU and Japan access search engines more frequently than any other type of online or offline information resource when looking for health information. As a result, consumers' requests for medication based on information obtained online have become an increasingly influential factor in the prescribing process.

eCME: Leveraging Online Continuing Medical Education as a Channel of Influence | $3800
The changing nature of CME has caused the pharmaceutical industry to reassess its investment in CME. While more restrictive guidelines and increased oversight may persuade many companies to decrease their investments in CME, Datamonitor recommends that stakeholders seize this opportunity to invest in educational programs that produce positive results in physician behavior and patient health.

From blockbuster to nichebuster - Niche therapies drive future drugs growth and incentivize R&D investment over sales spending | $1900
For 25 years, blockbusters have played a key role in driving strong drug market growth. However, pressure on blockbusters is increasing, as both regulators and payers are shifting away from me-too drugs, which in the past have been fertile ground for blockbusters. Furthermore, blockbusters attract significant generic competition and may also stifle R&D innovation.

GlaxoSmithKline: PharmaVitae Profile | $5695
This analysis examines the historical and forecast performance for GSK in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Eli Lilly: PharmaVitae Profile | $5695
This analysis examines the historical and forecast performance for Eli Lilly in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Novartis: PharmaVitae Profile | $5695
This analysis examines the historical and forecast performance for Novartis in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Pfizer: PharmaVitae Profile | $5695
This analysis examines the historical and forecast performance for Pfizer in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Merck Serono Biopharmaceuticals: PharmaVitae Profile | $5695
This analysis examines the historical and forecast performance for Merck Serono in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

UCB Schwarz: PharmaVitae Profile | $5695
This analysis examines the historical and forecast performance for UCB Schwarz in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Astellas: PharmaVitae Profile | $5695
This analysis examines the historical and forecast performance for Astellas in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Daiichi Sankyo: PharmaVitae Profile | $5695
This analysis examines the historical and forecast performance for Daiichi Sankyo in the pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Johnson and Johnson: PharmaVitae Profile | $5695
This analysis examines the historical and forecast performance for J&J in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Amgen: PharmaVitae Profile | $5695
This analysis examines the historical and forecast performance for Amgen in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Wyeth: PharmaVitae Profile | $5695
This analysis examines the historical and forecast performance for Wyeth in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Biogen Idec: PharmaVitae Profiles | $5695
This analysis examines the historical and forecast performance for Biogen Idec in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

King Pharmaceuticals: PharmaVitae Profile | $5695
This analysis examines the historical and forecast performance for King in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Abbott: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Abbott in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Chiron: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Chiron in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Monthly Wholesale Price Brief - A Review of European Gas and Power Price Trends: December 2006 | $2795
The growing role of wholesale traded energy markets across Europe creates a greater need for players throughout the value chain to be aware of the latest market movements and developments. From the wellhead or power station gate to the end-user, volatility in the spot and forward price of power and gas is creating an increasingly challenging environment for all market participants.

Fleet Lessor Profiler 2006 | $2795
The European fleet market has witnessed high levels of consolidation in the recent years. These profiles provide an insight into the competitive positioning of 15 companies amongst those dominating the market on a pan European basis.

European Light Commercial Vehicle Market | $27,495
The light commercial vehicle market continues to grow across Europe, driven by economic growth. This has a positive impact on the market for commercial vehicle rental and leasing. In several markets, a shift towards rental as a form of ownership has also helped to fuel market growth.

Bayer Schering Pharma: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Bayer Schering in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Schering AG: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Schering AG in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Allergan: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Allergan in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Shionogi: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Shionogi in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Lundbeck: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Lundbeck in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Genzyme: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Genzyme in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Pierre Fabre: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Pierre Fabre in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Eisai: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Eisai in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Merck & Co: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Merck & Co. in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Boehringer Ingelheim: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for BI in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Recordati: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Recordati in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Shire: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Shire in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Forest Laboratories: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Forest in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

AstraZeneca: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for AstraZeneca in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Novo Nordisk: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Novo Nordisk in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Serono: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Serono in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Takeda: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Takeda in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Altana: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Altana in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Sanofi-Aventis: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Sanofi-Aventis in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Schering-Plough: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Schering-Plough in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

MedImmune: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for MedImmune in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Akzo Nobel/Organon: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Akzo Nobel in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Financial Markets Research: Spectrum Pharmaceuticals' Oral Satraplatin - Oral therapy to take share in second-line hormone-refractory prostate cancer market | $3800
There are no FDA-approved second-line chemotherapy options for hormone refractory prostate cancer, indicating a great unmet need, with a large potential market for an agent such as Spectrum's satraplatin, which could offer key advantages due to its oral administration profile.

Financial Markets Research: Sirona Dental Systems - Likely struggle for impressive annual growth despite strong reputation and technology | $3800
Digital imaging products and CEREC form the basis for growth for Sirona Dental Systems, while accounting for nearly two-thirds of revenues, and will therefore be essential to the newly formed combination of Schick Technologies and Sirona.

Financial Markets Research: Palatin Technologies' Bremelanotide - Competition and regulatory risk cloud potential | $3800
Palatin Technologies' bremelanotide (PT-141) is a novel melanocortin receptor agonist that is believed to be the only agent currently in development for the treatment of both erectile dysfunction (ED) and female sexual dysfunction (FSD).

Financial Markets Research: Santarus, Inc.'s Zegerid - Fast-acting formulation gaining momentum in GERD | $3800
Following the lackluster 2004 launch of an oral suspension formulation of Santarus' lead product, Zegerid (a fast-acting proton pump inhibitor) much of Santarus' future success is tied to the commercial potential for the recently launched Zegerid oral capsule formulation to drive near-term revenues.

Financial Markets Research: Renovis, Inc.'s NXY-059 - Safety profile and unmet need could drive approval | $3800
Renovis and AstraZeneca's NXY-059 is viewed as the most promising neuroprotectant currently in development for stroke, however, much of its potential is dependent upon its ability to demonstrate a benefit in the recently enrolled SAINT-II trial.

Financial Markets Research: Endo Pharmaceuticals’ Lidoderm - Physician survey indicates increased use likely to fuel above-consensus sales growth | $3800
Launched in the US in 1999 as the only topical lidocaine patch, Lidoderm has demonstrated very strong growth year-on-year, with annual growth of 114% in 2003, 73% in 2004, and 36% in 2005. Lidoderm’s continued growth in both labeled and off-label indications is highly important to the company’s future success.

Financial Markets Research: Bausch & Lomb's Contact Lens Solution Withdrawal - ReNu MultiPlus likely to struggle in attempt to regain market share | $3800
In May 2006 Bausch & Lomb’s ReNu with MoistureLoc contact lens solution was permanently withdrawn from markets worldwide due to an outbreak of a fungal eye infection. For a large market player, the loss of a new revenue driver and the negative publicity surrounding the event is likely to have a significant impact on future success, as well as implications for other companies in the sector.

Financial Markets Research: ASCO Review Part II - A summary of highlights presented at the ASCO 2006 Annual Meeting | $3800
ASCO features key presentations in the oncology area, and is generally the most important week of the year for oncology. Presents Datamonitor’s comments on the most important events at the 2006 conference.

Financial Markets Research: ASCO Review Part I - A summary of highlights presented at the ASCO 2006 Annual Meeting | $3800
ASCO features key presentations in the oncology area, and is generally the most important week of the year for oncology. Presents Datamonitor’s comments on the most important events at the 2006 conference.

Financial Markets Research: Indevus Pharmaceuticals' Sanctura XR - Last-to-market entrant unlikely to make an impact in crowded OAB market | $3800
The lack of differentiation between overactive bladder agents has led manufacturers to turn to large-scale marketing efforts in an attempt to gain market share. Given the relatively small marketing capabilities of IDEV and Esprit, they may have difficulty penetrating high-prescribing urology and primary care practices compared to its larger rivals, thus slowing Sanctura XR’s near-term potential.

Genentech: PharmaVitae Profile | $5700
This analysis examines the historical and forecast performance for Genentech in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Roche: PharmaVitae Profile 2005 | $5700
This Company Analysis examines the historical and forecast performance for Roche in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides updated quantitative and qualitative information.

Commercial Insight: HIV - Change of guard | $15,200
The HIV market generated $7.4 billion of sales in 2005 and experienced a CAGR of 13.3% from 2001-2005, making it one of the fastest growing infectious diseases sub sectors. Despite the antiretroviral market's relative immaturity, many older flagship products such as Combivir are expected to lose patent protection before 2015.

Stakeholder Insight: Atherosclerosis - HDL, ApoA-I, Carotid MRI and 64-slice CT offer opportunities for future treatment | $15,200
Atherosclerosis generally begins in childhood and manifests clinically in mid-to-late adulthood. While the mortality from atherosclerotic conditions has declined significantly, in developed countries cardiovascular disease accounts for nearly 50% of all deaths, and within the next 15-20 years, is projected to surpass infectious diseases to become the leading cause of death worldwide.

Stakeholder Opinions: Melanoma - Lucrative commercial opportunities persist | $3800
Melanoma comprises just 5% of all skin cancers but it is the most deadly. In 2006, more than 100,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival of advanced patients remains below 20%.

Stakeholder Opinions: Respiratory Syncytial Virus (RSV) - A market yet to reach its full potential | $3800
RSV mostly causes upper respiratory tract infections (URTI), resulting in the common cold. However, in certain risk groups, RSV can cause more severe lower respiratory tract infections (LRTI) leading to bronchiolitis. These risk groups include elderly people, patients with underlying pulmonary or cardiac disease, premature infants, children under four years old and immunocompromised patients.

Stakeholder Insight: Multiple Sclerosis - Disease-modifying efficacy and side effects guide treatment choice | $15,200
The disease-modifying drugs are considered by physicians to represent a significant advance for the management of MS. However, none is fully effective and there are problems with regards to side effects, dosing regimens and cost. Tysabri, a novel once-monthly drug is expected to be an improvement in terms of efficacy; however, there remains a concern over side effects and long-term safety.

Commercial Insight: Osteoarthritis - Market sees steady growth | $15,200
The 2004 withdrawal of Vioxx from the global market had a negative effect on the COX-2 class, with a 44% fall in Celebrex sales for osteoarthritis in 2005. However, as patients sought an alternative to the COX-2s, there was positive growth in traditional NSAIDs, non-narcotic analgesics, narcotic analgesics, corticosteroids and HA viscosupplements, leading to a 1.1% increase in total market value.

Commercial and Pipeline Insight: Psoriasis - Anti-TNF's lead another indication | $15,200
There is no cure for psoriasis, which profoundly affects sufferers quality of life, physical and social functioning. There is a particular unmet need for effective long-term therapies for psoriasis. Prevalence is the highest of the autoimmune diseases at 16 million in 2006, but this is deceptive in terms of market size, as the treated and severe patient populations are comparatively small.

Stakeholder Opinion: Erectile Dysfunction - Identifying product differentiation and patient segmentation strategies | $3800
The erectile dysfunction market grew 3.5% from 2005 to be worth $1.95 billion in 2005 and is almost entirely composed of sales from three brands: Viagra (sildenafil), Cialis (tadalafil) and Levitra (vardenafil). Despite the dominance of these products, several opportunities exist for a successful market entry.

Commercial and Pipeline Perspectives: Obesity - Lack of Reimbursement Limits Market Potential | $11,400
Datamonitor predicts a somewhat enthusiastic uptake of two agents currently in development by 2015. However, reimbursement is critical to the uptake of new medication, due to the high cost of therapy. If the reimbursable status is not achieved, the expansion of the market will not match the rate of growth of the obese population and the great potential of the obesity market will remain untapped.

Pipeline Insight: Therapeutic Cancer Vaccines - A turbulent path from bench to bedside | $11,400
Unmet needs across the cancer market remain high, with most therapies conferring low levels of specificity and high toxicity. Therapeutic cancer vaccines offer an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. However, despite years of R&D, a reproducible survival benefit has proved elusive, leaving the market wide open.

Commercial Insight: Antibacterials - Growth in resistance rates drives niche indications | $15,200
The global antibacterial market, valued at $25.5 billion in 2005, is highly mature. Modest growth (CAGR 2001-2005: 5.1%) is fuelled by ageing, immunosuppression and emerging resistances, especially in the hospital and former niche markets (e.g. MRSA). The community market, however, is facing a value loss following the patent expiries of several blockbusters (e.g. Pfizer's Zithromax) in 2005.

Stakeholder Insight: Alzheimer's Disease - Prescribing trends indicate that neurologists are not adhering to guidelines | $15,200
A lack of prescriber adherence to both marketing licenses and pharmacoeconomic guidelines represents both a challenge and opportunity for pharmaceutical companies marketing current Alzheimer's disease drugs. Indication expansion between disease severities may not be a viable commercial option; conversely, stricter guidelines by bodies such as the UK's NICE will not necessarily threaten the market.

Biosimilars: Benchmarking the key players - With increasing regulatory clarity and high revenue potential, interest in biosimilars increases | $7600
With increasing regulatory clarity and the expiries of key patents covering innovator biologics, the development of biosimilars for a range of recombinant protein classes is becoming increasingly attractive. Although many companies are targeting the market, 12 companies dominate. These include established generics companies, leading biosimilars developers, plus emerging biosimilar developers.

Commercial Insight: Antithrombotics - Pipeline products to dampen the impact of patent expiries and cost containment initiatives | $15,200
The ageing of the population will result in an increased incidence of coronary artery disease, heart failure and stroke. In addition to these epidemiological forces, the antithrombotics market will be sustained by the forthcoming launch of innovative novel agents whose sales revenue is expected to dampen the commercial impact of generic incursion in blockbuster proceeds.

Pipeline Insight: Migraine - Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries | $11,400
After the launch of Trexima in 2007, triptan genericization coupled with a weak late-stage pipeline will result in a major shift in market dynamics, and will result in the migraine market value decreasing to $3.2 billion in 2015. The market remains receptive to superior prophylactics however, with innovation being essential for the progression of the acute market, post-triptan era.

Stakeholder Opinions: Gynecological Cancers - Niche opportunities in advanced disease | $3800
Cases of endometrial cancer are set to rise in developed countries due to an increase in risk factors such as obesity. In contrast, while incidence of cervical cancer is set to decrease in developed countries following the implementation of anti-HPV immunization with Merck & Co's Gardasil and GlaxoSmithKline's Cervarix, it will remain a major cause of cancer-related death in the developing world.

Stakeholder Insight: Pricing and Reimbursement in Oncology - Do payers believe oncology drugs offer good value? | $11,400
The oncology market has shown remarkable growth in recent years, driven by the advent of targeted therapy and the high level of unmet needs in the disease, and it is poised for further expansion. While this will provide companies with opportunities, a key hurdle for novel cancer drugs will be the increasing pharmacoeconomic vigilance that prevails within cash-strapped healthcare systems.

Changing Attitudes to Home Hygiene: From House-Proud To Carefree Consumers | $5695
Modern lifestyles have left consumers little time. As a result, household care and the way people utilize and live in their homes has evolved considerably. One of the most obvious differences has been the decline in personal time spent on domestic duties as consumers seek to maximize their leisure time with more enjoyment and socially orientated lifestyle activities.

Avon case study: embracing new opportunities in the cosmetics market | $295
This report on Avon forms part of Datamonitor's case studies series, which explores business practices across a variety of disciplines and business sectors. Each case study provides a concise evaluation of a company that stands out in some area of its strategic operations.

Biosimilars: Regulatory Issues - Europe continues to make strides while the US lags behind | $3800
The drive for increased cost savings by healthcare providers is increasing the focus on boosting the biosimilar market. With a regulatory approval pathway in place in Europe and substantial guidelines to support biosimilar development, the European biosimilars market is significantly more advanced than the US, where plans for a biosimilar regulatory approval pathway have stalled.

Commercial and Pipeline Insight: Inflammatory Bowel Disease - Competition Increases for the Biologics | $11,400
Ulcerative colitis and Crohn's disease are the primary constituents of Inflammatory Bowel Disease, which is estimated to affect approximately 1.8 million people in the seven major markets. Eight years after the launch of Remicade in Crohn's disease the next generation of anti-TNF's are poised for approval, but the anti-TNF class will soon be under attack from novel cytokine therapies.

Stakeholder Insight: Respiratory Tract Infections in the USA - The demise of narrow-spectrum antibiotics | $15,200
In the US, approximately 88 million people are diagnosed with a respiratory tract infection in an average year. Of these, a total of 66 million patients suffer from one of the three major diagnoses: acute bacterial sinusitis (ABS), acute exacerbation of chronic bronchitis (AECB) and community-acquired pneumonia (CAP).

Pipeline Insight: Breakthrough Pain - Fast-acting players will capture majority market share | $11,400
In spite of generic Actiq competition, Cephalon’s reign of the breakthrough pain market will be secured in the short-term with sales of its follow-on brand Fentora. From 2008, however, a number of fast-acting analgesics will enter the arena and battle for market share; this and other growth drivers will see the market more than double from 2005 to reach an estimated $2.5 billion in 2016.

Pipeline Insight: Osteoarthritis - The Wait for a DMOAD Continues | $11,400
Osteoarthritis (OA) is characterized by the progressive destruction of articular joints and is a major cause of pain in Western populations. Osteoarthritis is the most common form of arthritis and severely impacts the physical function and day-to-day quality of life of an individual. It also impacts heavily on the economy and it is believed to cost the US alone an estimated $60 billion per year.

Stakeholder Opinions: Hormonal Contraceptives - New directions in a competitive market | $3800
The hormonal contraceptive market grew by 4.2% from 2004 to $5.0 billion in 2005. Market growth was driven in part by the strong uptake of Schering AG's Yasmin and Organon's NuvaRing which fulfill key strategies: additional indications and alternative delivery modes. Market growth is not expected to falter if companies employ these lifecycle strategies which promote uptake in a competitive market.

Stakeholder Insight: Non-Small Cell Lung Cancer - The need for greater product differentiation in an increasingly crowded market | $15,200
NSCLC comprises over 75% of all lung cancers. In 2006, more than 338,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months.

Regulator Perceptions in Cancer - Evolving opinions about the oncology drug approval process | $1900
The oncology therapy area is unlikely to be spared from the heightened conservatism currently sweeping the regulatory environment. This is evidenced by the increased scrutiny with which the FDA appraises accelerated approval applications, particularly in light of the 2005 withdrawal of AstraZeneca's Iressa.

Pipeline Insight: Asthma/COPD - Targeted therapies on the horizon | $11,400
The total asthma and COPD population in 2006 is estimated to be 44.8 million and 28.8 million respectively. While the majority of patients are well controlled with current therapies, the remaining unmet needs are twofold: first, to find better options for the 1.7 million patients with severe asthma; second, to identify effective anti-inflammatory drugs in COPD.

Pipeline Insight: Epilepsy - Pipeline drugs struggle to outshine their marketed predecessors | $11,400
Slow generic uptake, reformulations, follow-on products and new market entrants will ensure steady long-term growth of the epilepsy market despite several high profile patent expiries. UCB has emerged as the number one epilepsy company, and is set to strengthen their epilepsy pipeline if the proposed acquisition of Schwarz is confirmed.

eSampling Strategies: Using Internet Technologies to Increase Impact at the Point of Care | $3800
The provision of samples to physicians is a key driver of pharmaceutical marketing success. eSampling can be a cost effective means of supplementing traditional drug sample distribution practices and should be used in combination with sales rep-based sampling efforts. Used effectively, eSampling can expand physician coverage and improve the quality of services provided to dedicated prescribers.

Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies - More drugs on the market, more targets in the pipeline | $15,200
Cancer treatment continues to embrace the inclusion of molecular targeted therapies (MTT) into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, commercial and strategic challenges are continuing to emerge.

Pipeline/Commercial Insight: Colorectal Cancer - Shaping the future dynamics of colorectal cancer management | $15,200
Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of Avastin and Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years.

Stakeholder Insight: Supportive Care in Cancer Treatment - Some first-generation products proving difficult to dislodge | $15,200
Supportive care is used to prevent or treat the adverse effects that arise as a result of cancer treatment, particularly chemotherapy. While newer molecular targeted therapies do not exist without some toxicity, this is not as severe as that associated with traditional cytotoxics. A rising incidence of cancer worldwide will mean that supportive care market will increase both size and relevance.

Stakeholder Insight: Atrial Fibrillation - Limited efficacy and poor safety lead to bleak outlook | $15,200
Datamonitor estimates that there are over 11 million atrial fibrillation patients in the seven major markets. Despite high unmet needs and limitations of all the current treatment options, achievement of regulatory approval is becoming increasingly difficult. This means that a very limited number of novel treatments are expected to be introduced in the near future.

Hip and Knee Replacement Market: Overview of the US and European markets - growth in a mature market | $3800
The orthopedic joint replacement market is at a crossroads between time-tested conventional procedures and advanced implant materials and surgical techniques. Demand driven by an aging population and an increasing number of younger patients undergoing replacement procedures together with improved implant materials and surgical techniques are contributing to growth in this mature market.

Advanced Life Sciences' Cethromycin - Phase III success should allow 'me-too' market entry and above-consensus growth | $3800
Traditionally, the treatment of respiratory infections has largely involved antibiotics from the macrolide class. Advanced Life Sciences' cethromycin, along with Sanofi-Aventis' Ketek, is a ketolide, a second-generation class of macrolides with activity against bacterial strains resistant to macrolides. Data from two Phase III trials in community-acquired pneumonia are expected in early 2007.

Pipeline Insight: Insulins - Inhalable insulins unlikely to become blockbusters | $11,400
Datamonitor expects the continuously growing prevalence of diabetes to drive growth in diabetes drug spending, potentially benefiting market uptake of novel insulin therapies. A set of novel, non-injectable insulins are poised to become available to patients in the next five years. By 2010, the market will thus have to absorb Pfizer's Exubera and at least three other inhalable insulins.

Commercial Insight: Antihypertensives - New challenges for a maturing market | $15,200
Datamonitor expects the antihypertensive market to exceed $40bn by 2015 across the seven major markets, with novel treatments and the market-leading ARBs delivering much of this value. However, significant hurdles exist, and pharmaceutical companies need to carefully design marketing campaigns and pricing structures for their products.

Pipeline Insight: HIV - Extending treatment options | $11,400
More people than ever are living with HIV and AIDS in North America and Western Europe. Over the next five years, a great variety of new HIV drugs are expected to reach the market early stage therapies will be simplified by new products that will transform the market. For those with few treatment options left, new pipeline products will redefine late stage therapy.

Stakeholder Insight: Rheumatoid Arthritis - Biologics battle up the treatment algorithm | $15,200
Rheumatoid arthritis is a debilitating and life-long disease that is estimated to affect approximately 5 million people in the seven major markets. The launch of anti-TNF products over six years ago and more recent novel target biologic therapies have added significantly to the treatment options, but have resulted in a crowded market for moderate to severe patients.

Commercial Insight: Antidiabetics - Patent expiries and cost containment initiatives balanced by pipeline products | $15,200
The diabetes epidemic has contributed to growth in the antidiabetics market over the past few years. Since the prevalence of diabetes continues to increase, the market will further expand. While early therapy is dominated by generically available agents, and the later stages by insulin, the number of unmet needs in the diabetes treatment warrants that novel agents will have a place in the market.

Pipeline Insight: Bipolar Disorder - New treatments for bipolar depression set to drive near-term growth | $11,400
Stimulated by sales of atypical antipsychotics for bipolar depression, and despite the launch of generic risperidone, the global bipolar disorder market will grow until 2011, when revenues will peak at $6.6 billion. The market will begin to decline thereafter owing to the launch of generic versions of the leading atypical antipsychotics, quetiapine, olanzapine, and ziprasidone from 2011 onwards.

Pipeline Insight: Parkinson's Disease and Restless Legs Syndrome - Reformulations set to drive near-term growth | $15,200
Despite affecting a large number of individuals, there are currently no treatments capable of curing either Parkinson's disease or Restless Legs Syndrome. Although available treatments are effective, numerous unmet needs prevail. Several compounds are in late-stage development and are forecast to achieve sales of $519m for Parkinson's disease and $399m for Restless Legs Syndrome in 2015.

Pipeline Insight: Non-insulin Antidiabetics - Type 2 diabetes unlikely to develop into a switch market | $11,400
Datamonitor expects the continuously growing prevalence of diabetes to drive growth in diabetes drug spending, benefiting market uptake of newly developed, efficacious therapies. A variety of novel, non-insulin antidiabetic agents are poised to become available to patients in the next decade, with two DPP-4 inhibitors likely to launch in 2007 and two GLP-1 agonists entering the market by 2010.

Commercial Insight: Asthma/COPD - ICS/LABA combinations continue to dominate | $15,200
The respiratory market will continue to experience strong growth for the next 6 years, driven by the expansion of sales in existing classes, the launch of major new products with safety and convenience advantages, and the results of several landmark studies. Despite patent expiries of three leading products, from 2010, the market will avoid a collapse like the one seen for oral antihistamines.

Commercial Insight: Neuropathic Pain - A Plethora of Patient Segmentation and Product Differentiation Opportunities | $15,200
Neurontin (gabapentin) has finally been knocked off the top spot as a result of fierce generic incursion. However, Pfizer's follow-on Lyrica (pregabalin), Lilly's Cymbalta (duloxetine) and Endo/Elan's Lidoderm (lidocaine patch 5%) are re-establishing market growth and laying the groundwork for new entrants.

Commercial Insight: Antidyslipidemics - Branded statins beware, generics are amongst you | $15,200
Commercial Insight: Antidyslipidemics explores current trends and key future issues in the management of dyslipidemia and the effects of generic competition and healthcare reforms on the main drug classes in this market. The growth potential of the leading classes is discussed, and case studies are used to highlight possible strategies to maximize future growth for lipid management franchises.

Pipeline Insight: Breast Cancer - A diverse and increasingly crowded pipeline | $11,400
Breast cancer is the leading cause of cancer-related mortality among women worldwide. In 2006, more than 447,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor type. Despite recent drug approvals in the adjuvant and metastatic setting, the overall survival remains below five years.

Pipeline Insight: Schizophrenia | $11,400
The global schizophrenia market will continue to grow until 2010, when revenues will reach $3.8 billion. However, despite the launch of numerous pipeline schizophrenia drugs, the market will begin to decline thereafter owing to the US launch of generic risperidone in 2007, followed by generic versions of olanzapine, quetiapine and ziprasidone from 2011 onwards.

Stakeholder Opinions: Parkinson's Disease - Review of Key Commercial Opportunities in the Symptomatic Treatment Market | $3800
Parkinson's disease (PD) is a progressive, degenerative condition of the central nervous system (CNS), caused by the degeneration of dopaminergic neurons in the substantia nigra of the midbrain. The PD market grew by 6.9% to $1.8 billion between 2004 and 2005. In the absence of conclusive evidence for a neuroprotective compound, the focus on the market remains on symptomatic treatment.

Pipeline Insight: Cancer Overview Emerging Therapeutic and Commercial Opportunities | $15,200
The 11 tumor types covered in this report will account for over 2.3 million new cases of cancer in 2006 in the seven major pharmaceutical markets. Despite the emergence of targeted therapies, major unmet needs remain. NSCLC and breast cancer attract the highest R&D interest, but niche tumors with high unmet needs are gaining significant interest from pharmaceutical and biotech companies.

Commercial Insight Top 20 Cancer Therapeutics | $15,200
The Top 20 cancer therapeutics generated sales of $20.1 billion in 2005 across the seven markets, set to reach $27.4 billion by 2015. Cytotoxics currently constitute the majority, due to their long history in oncology and their key role in current treatment. By 2015, the majority of the Top 20 will consist of targeted therapies, whose place in cancer therapy will become increasingly established.

Stakeholder Opinions: Ovarian Cancer Growing importance as secondary indication for targeted therapies | $3800
Despite being the most common cause of death from gynecological tumors, ovarian cancer has not traditionally attracted the same level of R&D interest as other female cancers. Nevertheless, nearly 60,000 cases of ovarian cancer being diagnosed in the seven major markets each year is, by no means, small and therefore, it remains an important secondary indication for existing and pipeline drugs.

Commercial Insight: Transplantation | $15,200
In 2005, over 50.000 solid organ transplants were conducted in the seven major markets. In order to prevent the patient's immune system from rejecting the transplanted organ, immunosuppression therapy is required for the lifetime of the graft with a base maintenance drug (either Calcineurin- or mTOR inhibitors) and adjunctive therapies (antimetabolites, steroids).

Stakeholder Opinions: Systemic Lupus Erythematosus - On the Verge of a Breakthough | $3800
Systemic Lupus Erythematosus is a chronic, life-long and potentially fatal autoimmune disease characterized by multiple system distress and unpredictable flares. High unmet need makes this an attractive market but dispute over patient numbers and clinical trial difficulties are significant hurdles for new entrants to overcome.

Pipeline Insight: Hepatitis C - Protease inhibitors to drive market expansion | $11,400
An estimated 10 million people in the seven major markets have chronic HCV. The current standard of care, pegylated interferon (Peg-IFN) plus ribavirin (RBV), achieves long-term disease remission in approximately half of those receiving treatment. More efficacious therapies are required to improve treatment success in difficult-to-treat patients, in particular patients with HCV genotype 1.

Management of Urinary Incontinence and Overactive Bladder - A Global Overview | $15,200
Although there are many marketed treatments for overactive bladder, there are few available for stress urinary incontinence or interstitial cystitis. Furthermore, despite available treatments for overactive bladder, many are associated with side effects leading to poor treatment compliance. With significant unmet needs remaining in these markets, there are clear opportunities for new entrants.